mHealth Intelligence March 6, 2024
Pandemic-era flexibilities that allow the initiation of OUD treatment via telehealth and take-home doses of medications are likely cost-effective, research shows.
Regulatory flexibilities enabling virtual initiation and at-home doses of medications for opioid use disorder (OUD) are likely cost-effective, according to new research.
Published in the journal Drug and Alcohol Dependence, the study aimed to assess the effectiveness and cost-effectiveness of buprenorphine and methadone treatment provided through expanded regulations enacted during the COVID-19 pandemic.
Federal agencies enacted numerous waivers to curb healthcare access challenges resulting from in-person care restrictions during the pandemic. Among these was an exception issued by the Substance Abuse and Mental Health Services Administration (SAMHSA), which allowed healthcare providers to initiate buprenorphine treatment via telehealth and offer...
Today's Sponsors
Today's Sponsor